Matthew Bower, MD
Surgical Oncology · Temple, TXNPI 1912115874
Payments from drug & device makers
What this record shows
This record is dominated by education: $21,209 of the $22,404 with a category attached, or 94.7%. Intuitive Surgical accounts for 98.0% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $15,737 and has fallen 98.7% since, to $211 in 2025.
Across 27 payments — averaging $829.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$22K
- Elucent Medical$157
- Integra Lifesciences Corporation$153
- Johnson & Johnson$59
- Tactile Systems Technology Inc$35
- Genentech USA, Inc.$32
- plus $22 from 1 others
Across 7 payments — averaging $11,413 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$80K
What the payments were for
- Food & beverage$1,1955%
- Education$21,20995%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 18 | $21,946 |
| Elucent Medical | 1 | $157 |
| Integra Lifesciences Corporation | 1 | $153 |
| Johnson & Johnson(2 entities) | 2 | $59 |
| Tactile Systems Technology Inc | 2 | $35 |
| Genentech USA, Inc. | 2 | $32 |
| Hologic Sales And Service, LLC | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$15,759
- DAVINCI XI$6,000
- CODMAN CERTAS$153
- CUSA CLARITY$153
- DURAGEN$153
- DURASEAL EXACT$153
- CODMAN HAKIM PRECISION VALVE$153
How this compares
$22,404 in reported general payments places this provider in the 85th percentile of 191 surgical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 50 | $127 |
| Tramadol Hcl | 14 | $21 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Temple
- Allison DipasqualeDallas$272K
- Merrick RossHouston$216K
- John HardawayShenandoah$164K
- Steven CurleyTyler$162K
- Suhail SharifFort Worth$137K
- Alfredo Santillan GomezSan Antonio$125K
- Kelly HuntHouston$104K
- Adam YoppDallas$96K
- Peter BeitschDallas$62K
- Patricio PolancoDallas$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.